Abstract
Female genital myeloid sarcoma (MS), especially vulvar MS, should be included in the differential diagnosis of gynecological neoplasms. Early recognition facilitates prompt diagnosis and management, which is critical given its frequent association with systemic leukemia.
Introduction
Myeloid sarcoma (MS) is a rare, aggressive extramedullary tumor composed of immature myeloid blasts. While it most commonly affects the skin, lymph nodes, or gastrointestinal tract, its appearance in the female genital tract is exceptionally rare. Vulvar involvement, in particular, is among the least documented presentations. Because these lesions often mimic primary gynecological cancers or lymphomas, they pose a significant diagnostic challenge. This report details a case of vulvar MS serving as the primary warning sign of acute myeloid leukemia (AML) and provides a comprehensive review of 54 similar cases in the Chinese population from 1999 to 2018.
Case Presentation and Diagnostic Methodology
A 47-year-old woman presented with chronic, non-healing vulvar ulcers. To differentiate the lesion from more common gynecological malignancies, clinicians performed an incisional biopsy. The diagnosis of MS relies heavily on histopathology and a specific panel of immunohistochemical (IHC) markers.
As shown in the IHC panel, the tumor cells expressed markers such as myeloperoxidase (MPO), lysozyme, and CD68, confirming their myeloid lineage. Subsequent bone marrow flow cytometry confirmed a diagnosis of systemic AML, specifically the M2 subtype. This case underscores the necessity of IHC in distinguishing MS from other small round cell tumors like lymphoma.
Literature Review: The Chinese Population (1999–2018)
The authors conducted a retrospective analysis of 54 cases of gynecological MS reported in Chinese medical databases. This cohort represents one of the largest regional reviews of this pathology, offering key epidemiological insights:
- Site Distribution: The uterine cervix was the most common site of involvement (40%), followed by the ovaries (23.6%) and the vulva (10.9%).
- Age of Onset: A notable correlation exists between the site of involvement and patient age. Ovarian MS tends to occur in younger women (average age ~27), whereas cervical and vulvar MS typically present in the fourth decade of life (average age ~40-43).
- Systemic Correlation: Vulvar MS demonstrated a high rate of concurrent systemic disease; 66.7% of vulvar cases coincided with the onset of AML, suggesting that the vulvar lesion is often a "herald" for widespread leukemia.
- Subtype Predominance: Interestingly, while international literature often associates MS with AML subtypes M4 and M5, this Chinese cohort showed a predominance of the M2 subtype (10 cases), indicating potential regional biological variations.
Discussion and Clinical Insights
One of the most critical findings is the "ulcer red flag." While MS in the cervix or ovaries usually presents as a palpable mass, vulvar MS frequently manifests as chronic ulceration. This makes it a vital differential diagnosis for any non-healing genital ulcer that does not respond to standard treatments.
Prognostically, MS remains a high-risk condition with a 5-year survival rate of approximately 20%. However, the patient in this case report achieved complete remission following induction chemotherapy (idarubicin and cytarabine) and remained disease-free at a 27-month follow-up. Current evidence suggests that aggressive systemic chemotherapy, often followed by hematopoietic stem cell transplantation (HSCT), offers the best chance for long-term survival, even when the disease appears localized initially.
Conclusion
Vulvar myeloid sarcoma is a rare but critical diagnostic consideration. Its presentation as an ulcer requires urgent systemic screening for leukemia. Increased clinical awareness and the routine use of IHC panels are essential to prevent misdiagnosis and ensure that patients receive life-saving systemic therapy promptly.
Summary updated